文献速递白血病淋巴瘤

培门冬酶与卡拉斯帕酶在儿童急性淋巴细胞白血病中的疗效与毒性:DFCI 11-001研究结果

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
PubMed 文献 · J Clin Oncol · 2021-07-06

DFCI 11-001研究随机比较了培门冬酶与新型长效聚乙二醇化门冬酰胺酶卡拉斯帕酶在儿童急性淋巴细胞白血病/淋巴母细胞淋巴瘤中的疗效与毒性。结果显示,每3周卡拉斯帕酶与每2周培门冬酶在谷浓度、毒性及5年无事件生存率上相似,且卡拉斯帕酶在诱导后第25天更多患者维持治疗性血清门冬酰胺酶活性。

要点

  • 卡拉斯帕酶每3周与培门冬酶每2周方案在谷浓度、毒性和生存上相似。
  • 诱导后第25天,卡拉斯帕酶组88%患者SAA≥0.1 IU/mL,培门冬酶组仅17%。
  • 两种制剂毒性(过敏、胰腺炎、血栓、高胆红素血症)无差异。

核心结论

  • 每3周卡拉斯帕酶与每2周培门冬酶在谷浓度、毒性和生存结局上相似。
  • 两种制剂观察到的较高谷浓度提示给药策略可进一步优化。

研究设计与样本

  • 多中心随机对照试验,纳入1至≤21岁新诊断ALL或淋巴母细胞淋巴瘤患者。
  • 共239例 eligible 患者随机分配,120例培门冬酶,119例卡拉斯帕酶。
  • 培门冬酶每2周15次,卡拉斯帕酶每3周10次,共30周;剂量均为2500 IU/m2/次。

主要发现

  • 诱导后第18天,两组≥95%患者SAA≥0.1 IU/mL;第25天卡拉斯帕酶组88% vs 培门冬酶组17%(P<.001)。
  • 诱导后中位谷浓度两组相似(≥1.0 IU/mL)。
  • 可评估230例中,完全缓解率培门冬酶99% vs 卡拉斯帕酶95%(P=.12)。
  • B-ALL可评估患者中,诱导末高危微小残留病频率无差异。
  • 中位随访5.3年,5年无事件生存率培门冬酶84.9%(SE±3.4%) vs 卡拉斯帕酶88.1%(SE±3.0%)(P=.65)。

关键数值与推荐

  • 血清门冬酰胺酶活性≥0.1 IU/mL视为治疗性。
  • 卡拉斯帕酶每3周给药与培门冬酶每2周给药在谷浓度、毒性和生存上等效。

临床怎么用

  • 卡拉斯帕酶每3周方案可作为培门冬酶每2周方案的替代,且给药频率更低。
  • 两种制剂均可实现高谷浓度,提示可探索进一步优化给药策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase), a novel pegylated asparaginase formulation with longer half-life, compared with the standard formulation pegaspargase. METHODS: Patients age 1 to ≤ 21 years with newly diagnosed ALL or lymphoblastic lymphoma were randomly assigned to intravenous pegaspargase or calaspargase, 2,500 IU/m2/dose. Patients received one induction dose. Beginning week 7, pegaspargase was administered every 2 week for 15 doses and calaspargase every 3 week for 10 doses (30 weeks). Serum asparaginase activity (SAA) (≥ 0.1 IU/mL considered therapeutic) was assessed 4, 11, 18, and 25 days after the induction dose and before each postinduction dose. RESULTS: Between 2012 and 2015, 239 eligible patients enrolled (230 ALL, nine lymphoblastic lymphoma); 120 were assigned to pegaspargase and 119 to calaspargase. After the induction dose, SAA was ≥ 0.1 IU/mL in ≥ 95% of patients on both arms 18 days after dosing. At day 25, more patients had SAA ≥ 0.1 IU/mL with calaspargase (88% v 17%; P ˂ .001). Postinduction, median nadir SAAs were similar (≥ 1.0 IU/mL) for both arms. Of 230 evaluable patients, 99% of pegaspargase and 95% of calaspargase patients achieved complete remission (P = .12), with no difference in frequency of high end-induction minimal residual disease among evaluable patients with B acute lymphoblastic leukemia (B-ALL). There were no differences in frequencies of asparaginase allergy, pancreatitis, thrombosis, or hyperbilirubinemia. With 5.3 years median follow-up, 5-year event-free survival for pegaspargase was 84.9% (SE ± 3.4%) and 88.1% (± SE 3.0%) for calaspargase (P = .65). CONCLUSION: Every 3-week calaspargase had similar nadir SAA, toxicity, and survival outcomes compared with every 2-week pegaspargase. The high nadir SAA observed for both preparations suggest dosing strategies can be further optimized.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vrooman LM, Blonquist TM, Stevenson KE, et al. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021. PMID: 34228505. doi:10.1200/JCO.20.03692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。